The expected outcomes of HMN-372 include:
“In Parkinson’s, we’ve been limited to symptomatic dopamine replacement. The modest motor improvement seen in the Phase IIa trial suggests we’re finally addressing the upstream neuro‑inflammatory cascade that drives neuronal loss.” HMN-372
Analysts at Bionomics Research assign a , positioning HMN‑372 in the mid‑range of disease‑modifying AD therapies. HMN-372